Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the DPP-4 inhibitor linagliptin slowed the progression of premature aging characteristics in klotho-/- mice, including improved body weight, cognitive function, and hair retention.

This case report describes a 68-year-old man who developed both alopecia areata and bullous pemphigoid after starting linagliptin for diabetes, suggesting a possible link with DPP-4 inhibitors.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This case report describes a 35-year-old male with Type 2 diabetes who experienced scalp hair loss after increasing his dose of Teneligliptin without supervision, which resolved after discontinuing the medication.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

This case report suggests an association between the use of Sitagliptin, a DPP-4 inhibitor, and the development of alopecia universalis in a diabetic patient.

GLP-1 and GLP-1/GIP agonists may increase the risk of hair loss.

This study suggests that among GLP-1 agonists, liraglutide and exenatide are linked to the highest rates of gastrointestinal issues, including potentially pancreatitis-related enzyme changes noted in animal models.

This study found that GLP1-RAs, while not triggering significant safety signals, were reported more often for suicide, hair loss, and aspiration events compared to some other diabetes medications.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.

Pioglitazone may help treat lichen planopilaris, but more research is needed.

This study observed that, among women of reproductive age with prediabetes, those treated with a combination of metformin and liraglutide experienced greater weight loss, a more significant decrease in visceral adiposity index, and higher rates of HbA1C normalization compared to those receiving metformin and inositol.

In this case study, a man with Werner syndrome and diabetes saw improved glycemic control and insulin resistance with dapagliflozin, suggesting its potential usefulness for managing diabetes in similar patients.

Eating shiitake mushrooms caused a man to develop a rash similar to a skin condition known as AGEP.

This review discusses the etiology, diagnosis, and management of polycystic ovary syndrome and reports no new clinical findings.

In this study, analysis of electronic health records suggested that patients taking semaglutide were significantly less likely to experience suicidal ideation compared to those on non-GLP-1 obesity or diabetes medications.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

This review suggests that glucagon-like peptide 1 receptor agonists may play a potentially protective role in managing diabetic foot ulcers, particularly by addressing various underlying pathophysiological aspects.

This study observed an increased risk of alopecia areata among new users of GLP-1 agonists semaglutide and liraglutide compared to users of bupropion-naltrexone, highlighting potential hair loss concerns with these medications.

In this study, short-term liraglutide treatment led to significant weight loss in obese women with newly diagnosed PCOS and a higher metabolic risk profile compared to metformin.

This review discusses the dermatologic side effects and potential therapeutic benefits of GLP-1 receptor agonists, such as facial fat loss and wound healing, emphasizing the need for further research.

This study found that combining liraglutide with metformin led to greater weight loss and waist circumference reduction than either treatment alone in obese women with PCOS resistant to metformin monotherapy.

This study supports the traditional use of T. procumbens for diabetes treatment, showing improvements in body weight and glucose tolerance with no toxicity signs in normal rats.

This study found that adults with type 2 diabetes or obesity using semaglutide and tirzepatide experienced higher odds of nonscarring alopecia, such as telogen effluvium, compared to those using other GLP-1 receptor agonists, with hair loss potentially linked to physiologic stress from weight loss.

This research highlights the lack of clinical evidence linking GLP-1 agonists, commonly used in treating type 2 diabetes and obesity, to hair loss, despite theoretical concerns regarding potential hair health impacts.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This study utilized a UHPLC-HRMS method to identify eight active pharmaceutical ingredients, such as ketoconazole and minoxidil, in 26 out of 100 analyzed cosmetic products.